K. Nishikawa

发表

DNA-Dependent Protein Kinase and Ataxia Telangiectasia Mutated (ATM) Promote Cell Survival in Response to NK314, a Topoisomerase IIα Inhibitor

Lei Guo, Xiaojun Liu, Ying-jun Jiang, 2011, Molecular Pharmacology.

Topoisomerase-II Inhibitor

Lei Guo, Xiaojun Liu, Ying-jun Jiang, 2011 .

Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

N. Taira, S. Takashima, K. Nishikawa, 2009, Breast cancer.

DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS

K. Nishikawa, I. Ikemoto, D. Nagai, 2006, Drug Metabolism and Disposition.

Suppression of mutant androgen receptors by flutamide

K. Nishikawa, J. Isaacs, J. Ishioka, 2009, International journal of urology : official journal of the Japanese Urological Association.

Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis.

K. Nishikawa, I. Saiki, K. Koizumi, 2006, Cancer letters.

Immunohistochemical expression of aminopeptidase N (CD13) in human lung squamous cell carcinomas, with special reference to Bestatin adjuvant therapy

T. Nakajima, K. Nishikawa, F. Abe, 2006, Pathology international.

Augmentation of death ligand‐induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines

K. Nishikawa, F. Abe, H. Fujii, 2001, International journal of cancer.

NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.

T. Onda, K. Nishikawa, K. Okamoto, 2008, Cancer letters.

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics

H. Yamanaka, K. Nishikawa, T. Takeuchi, 2021, Modern Rheumatology.

NK95806, a newly synthesized microtubule-disrupting agent that suppresses collagen-induced arthritis in mice.

K. Nishikawa, F. Abe, E. Ichimura, 2004, International immunopharmacology.

Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice

K. Nishikawa, Y. Matsuzaki, D. Nagai, 2006, Journal of Gastroenterology.

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

T. Hibi, K. Nishikawa, Mamoru Watanabe, 2021, Journal of gastroenterology and hepatology.

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

T. Hibi, K. Nishikawa, Mamoru Watanabe, 2019, Intestinal research.

Inhibition of topoisomerase IIα and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials

Lei Guo, Xiaojun Liu, K. Nishikawa, 2007, Molecular Cancer Therapeutics.

Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.

K. Nishikawa, K. Tamura, K. Hashimoto, 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

ANovel Compound , NK 150460 , Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2015 .

A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2014, Molecular Cancer Therapeutics.

Studies on the chemical constituents of stem bark of Millettia leucantha: isolation of new chalcones with cytotoxic, anti-herpes simplex virus and anti-inflammatory activities.

K. Nishikawa, V. Lipipun, N. Ruangrungsi, 2003, Chemical & pharmaceutical bulletin.

Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation*

T. Tsuruo, K. Nishikawa, M. Naito, 2008, Journal of Biological Chemistry.

Expression profiling to predict postoperative prognosis for estrogen receptor‐negative breast cancers by analysis of 25,344 genes on a cDNA microarray

Tatsuhiko Tsunoda, Yoshio Miki, Fujio Kasumi, 2004, Cancer science.

Type-specific Regulation of Adenylyl Cyclase

I. Sakai, Y. Toya, K. Nishikawa, 2001, The Journal of Biological Chemistry.

NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*

K. Nishikawa, H. Koyama, N. Adachi, 2008, Journal of Biological Chemistry.

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

K. Nishikawa, M. Ohtsuki, A. Morita, 2022, The Journal of dermatology.

Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf‐1 activation

L. Neckers, Yukihiro Asami, K. Nishikawa, 2008, Cancer science.

Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR 2 , EGFR , FGFR

K. Nishikawa, T. Usui, H. Kakeya, 2008 .

Identification of RAI3 as a therapeutic target for breast cancer.

M. Emi, K. Nishikawa, A. Tomura, 2005, Endocrine-related cancer.

Identification of RAI3 as a therapeutic target for breast cancer.

M. Emi, K. Nishikawa, A. Tomura, 2005, Endocrine-related cancer.

Cell cycle arrest and antitumor activity of pironetin and its derivatives.

K. Tsuchiya, K. Nishikawa, S. Kobayashi, 1998, Cancer letters.

The Anticancer Natural Product Pironetin Selectively Targets Lys352 of α-Tubulin

K. Nishikawa, H. Watanabe, H. Nakayama, 2004 .

Heliquinomycin, a new inhibitor of DNA helicase, produced by Streptomyces sp. MJ929-SF2 II. Structure determination of heliquinomycin.

K. Nishikawa, H. Naganawa, T. Takeuchi, 1997, The Journal of antibiotics.

Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.

K. Nishikawa, T. Usui, H. Kakeya, 2008, Oncology Research.

Heliquinomycin, a new inhibitor of DNA helicase, produced by Streptomyces sp. MJ929-SF2 I. Taxonomy, production, isolation, physico-chemical properties and biological activities.

K. Nishikawa, T. Takeuchi, T. Sawa, 1996, The Journal of antibiotics.

The anticancer natural product pironetin selectively targets Lys352 of alpha-tubulin.

K. Nishikawa, H. Nakayama, K. Takio, 2004, Chemistry & biology.